Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: The need for continued vigilance

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 938-939

  Chew, Edward ^a   Thursky, Karin ^a   Seymour, John F ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; LAMIVUDINE; RITUXIMAB; TENOFOVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

DISEASE SURVEILLANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LETTER; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; PRIORITY JOURNAL; VIRUS REACTIVATION; CASE REPORT; CHEMOPROPHYLAXIS; COMPLICATION; DRUG EFFECTS; MALE; MIDDLE AGED; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; WALDENSTROM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CHEMOPREVENTION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; VIRUS ACTIVATION; WALDENSTROM MACROGLOBULINEMIA;

EID: 84902661966     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.813502     Document Type: Letter

References (10)

1. Ram R, Ben-Bassat I, Shpilberg O, et al . The late adverse events of rituximab therapy-rare but there! Leuk Lymphoma 2009; 50 : 1083-1095 .
2. Thompson PA, Tam CS, Thursky K, et al . Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge . Leuk Lymphoma 2010; 51: 1592- 1595.
3. G astroenterological Society of Australia Digestive Health Foundation . Australian and New Zealand chronic hepatitis B (CHB) recommendations [Internet] . Gastroenterological Society of Australia 2009 .
4. [Accessed 20 Mar 2013]. Available from: http://www.gesa.org.au/ professional.asp?cid 26 & id 51
5. Liaw YF, Kao JH, Piratvisuth T, et al . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update . Hepatol Int 2012; 3 : 531-561 .
6. Lok AS, McMahon BJ . Chronic hepatitis B: update 2009 . Hepatology 2009; 50 :661-662.
7. Artz AS, Somerfield M R, F eld J J, et al. A merican Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases . J Clin Oncol 2010; 28 : 3199-3202 .
8. European Association for the Study of the Liver . EASL clinical practice guidelines: management of chronic hepatitis B virus infection . J Hepatol 2012; 57 : 167-185 .
9. E vens A M, J ovanovic B D, S u Y V, et al. R ituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports . Ann Oncol 2011; 22 : 1170-1780 .
10. Lok AS, Lai CL, Wu PC, et al . Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection . Gastroenterology 1987; 92 : 1839-1843 . (Pubitemid 17072230)